Betta Pharmaceuticals

Reprogenix is a groundbreaking medical technology firm that began with stem cell therapy for diabetes and is dedicated to expanding the use of cell therapy in a wide range of disease areas.

Gaowei Medicine is a drug discovery platform for developing new drugs for key intractable diseases such as cancer and neurological diseases.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates that target and eliminate disease-causing proteins, primarily for the treatment of cancer and neurodegenerative disorders. The company's lead product candidate, CFT7455, is an orally bioavailable degrader designed to target IKZF1/3 for multiple myeloma and other lymphomas. Additionally, C4 is advancing CFT8634, which targets BRD9 for specific solid tumors, alongside programs aimed at genetically defined resistant solid tumors. C4 Therapeutics utilizes its proprietary Degronimid platform, which allows for the selective degradation of proteins through the natural ubiquitin/proteasome system, potentially addressing previously undruggable targets while minimizing drug resistance. The company has formed strategic collaborations with major industry players, and it aims to make a significant impact on the treatment landscape through its advanced protein degradation science and multiple development programs. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics continues to innovate in the field of targeted therapy.

E-nitiate Biopharmaceuticals is committed to the development of innovative drugs for autoimmune diseases, through independent research and development, and strategic collaborations, to address unmet medical needs and to improve the quality of human life.

Centrymed is a biotechnology company specializing in the development of antibody drugs for tumor treatment and autoimmune diseases. It has established a proprietary dual-antibody platform, which includes human dAb libraries and bispecific antibodies, granting it independent intellectual property rights. The company has successfully created over 20 unique antibody drugs that target various solid tumors and stages of immune diseases, addressing significant clinical and patient needs while mitigating the challenges of drug drugability and the toxic side effects commonly associated with antibody therapies.

Capio Biosciences is a biotechnology company dedicated to advancing oncology diagnostics that enhance patient care and outcomes. The company is developing an innovative platform known as CapioCyte™, which captures circulating tumor cells (CTCs) from whole blood with superior sensitivity compared to existing technologies. This platform employs a unique combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, allowing for the enrichment of CTCs suitable for comprehensive molecular analyses, including FISH, RNA-Seq, and NGS. CapioCyte™ is designed to meet the needs of contemporary cancer research and holds potential for future applications in clinical patient management. Additionally, Capio Biosciences aims to provide personalized treatment therapies that assist in the removal of cancer cells from patients' bodies through liquid biopsies, ensuring that healthcare providers can effectively address their patients' needs.

Hangzhou DAC Biotech Co., Ltd. is a biotechnology company established in 2012 and located in Hangzhou, China, specializing in the development of cancer treatment drugs. The company offers an antibody-drug conjugate (ADC) platform that features over 50 innovative linkers for site-specific conjugation, along with five series of high-activity small molecule compounds that function through various mechanisms. Hangzhou DAC Biotech also excels in antibody discovery, engineering transformation, and optimizing production processes. Additionally, the firm provides comprehensive services including in vivo and in vitro evaluations of ADC drugs, drug structure confirmation, and the development and verification of analytical methods.

Xcovery LLC is a biopharmaceutical company based in Palm Beach Gardens, Florida, founded in 2006. It specializes in the development of targeted oncology therapies designed to address various advanced tumors. The company is known for its lead compound, X-396, a small molecule that inhibits anaplastic lymphoma kinase, along with other kinase inhibitors targeting MET and PI3K/mTOR pathways. Xcovery aims to create low-toxicity oral drugs that facilitate continuous therapy without the need for dosing interruptions, thereby enhancing treatment efficacy and safety for cancer patients. This approach allows for a broader therapeutic window and the potential for combination therapies without the toxicity associated with current treatments. The leadership team includes experienced professionals from notable biotech backgrounds, contributing to the company's innovative research and development efforts in oncology.